FDA
-
-
-
-
-
-
-
Cellectar receives rare pediatric disease designation for brain cancer drug
-
-
-
-
-
-
-
Cellectar Biosciences Announces European Medicines Agency (EMA) Confirms Eligibility to File for Conditional Marketing Authorization (CMA) for Iopofosine I 131 as a Treatment for Refractory (post-BTKi
-
-
-
-
-
-
-
Cellectar Biosciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
-
-
-
-
-
-
-
Cellectar Biosciences (CLRB) Provides Update on CLOVER-2 Phase 1 Trial
-
-
-
-
-
-
-
Cellectar Biosciences Reports First Quarter 2025 Financial Results and Provides a Corporate Update
-
-
-
-
-
-
-
Cellectar Biosciences to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
-
-
-
-
-
-
-
Cellectar Biosciences and NorthStar Medical Radioisotopes Announce Partnership for Supply of Actinium-225
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

